Related Experiment Videos
Dose-response of simvastatin in primary hypercholesterolemia
J Tuomilehto1, A C Guimaraes, H Kettner
1Department of Epidemiology, National Public Health Institute, Helsinki, Finland.
Journal of Cardiovascular Pharmacology
|December 1, 1994
Summary
Simvastatin effectively lowers high cholesterol (TCHOL) and low-density lipoprotein (LDL) cholesterol in patients. Higher doses showed greater reductions and improvements in lipid profiles with no serious adverse events.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Hypercholesterolemia is a significant risk factor for cardiovascular disease.
- Statins are a cornerstone therapy for managing elevated cholesterol levels.
- Understanding the dose-response relationship of new statins is crucial for effective treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of various simvastatin doses in patients with hypercholesterolemia.
- To determine the dose-response relationship for lipid-lowering effects.
- To assess the impact of simvastatin on total cholesterol, LDL cholesterol, triglycerides, and HDL cholesterol.
Main Methods:
- An 8-week, placebo-controlled, multicenter study.
- 166 patients with hypercholesterolemia were enrolled.
- Patients received simvastatin at doses of 2.5, 5, 10, 20, or 40 mg, or placebo.
Main Results:
- Simvastatin demonstrated a statistically significant, dose-dependent reduction in total cholesterol (TCHOL) and LDL cholesterol.
- Higher simvastatin doses (≥ 5 mg) also increased HDL cholesterol and reduced triglycerides (TG).
- 55% of patients on 40 mg simvastatin achieved a ≥ 40% reduction in LDL cholesterol; 55% reached TCHOL < or = 5.2 mM.
Conclusions:
- Simvastatin is effective in improving the serum lipoprotein profile of patients with hypercholesterolemia.
- A significant linear dose-response was observed for lipid reduction and HDL increase.
- Simvastatin was well-tolerated across all tested dose levels, with no serious adverse events reported.